AR115927A2 - Derivados de tetrahidro-pirido-pirimidina - Google Patents
Derivados de tetrahidro-pirido-pirimidinaInfo
- Publication number
- AR115927A2 AR115927A2 ARP190102244A ARP190102244A AR115927A2 AR 115927 A2 AR115927 A2 AR 115927A2 AR P190102244 A ARP190102244 A AR P190102244A AR P190102244 A ARP190102244 A AR P190102244A AR 115927 A2 AR115927 A2 AR 115927A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylcarbonyl
- alkoxy
- hydroxy
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un derivado de tetrahidro-pirido-pirimidina de la fórmula (1) y/o las sales farmacéuticamente aceptables del mismo, en donde: Y se selecciona a partir de O ó NR³; R¹ se selecciona a partir de fenilo, piridilo, pirimidinilo, pirazinilo, piridazinilo, 1,2,3-triazinilo, 1,2,4-triazinilo, 1,3,5-triazinilo, o -C(O)-R⁴; en donde: R⁴ se selecciona a partir de alquilo C₁₋₈, halo-alquilo C₁₋₈, hidroxi-alquilo C₁₋₈, alcoxilo C₁₋₈-alquilo C₁₋₈, alquilo C₁₋₈-sulfonil-alquilo C₁₋₈, heterociclilo, heterocicliloxilo, heterociclil-alquilo C₁₋₈, cicloalquilo C₃₋₁₂, cicloalquilo C₃₋₁₂-alquilo C₁₋₈, heteroarilo, heteroariloxilo, heteroaril-alquilo C₁₋₈, hidroxilo, alcoxilo C₁₋₈, amino, N-alquilo C₁₋₈-amino, o N,N-di-alquilo C₁₋₈-amino; en donde alquilo C₁₋₈ en N-alquilo C₁₋₈-amino y N,N-di-alquilo C₁₋₈-amino puede estar insustituido o sustituido por halógeno, hidroxilo, o alcoxilo C₁₋₄; en donde cicloalquilo C₃₋₁₂ en cicloalquilo C₃₋₁₂ y cicloalquilo C₃₋₁₂-alquilo C₁₋₈ puede estar insustituido o sustituido por 1 a 5 sustituyentes seleccionados independientemente a partir de oxo, halógeno, alquilo C₁₋₈, halo-alquilo C₁₋₈, hidroxi-alquilo C₁₋₈, hidroxilo, alcoxilo C₁₋₈, alcoxilo C₁₋₈-alquilo C₁₋₈, amino, N-alquilo C₁₋₈-amino, N,N-di-alquilo C₁₋₈-amino, alquilo C₁₋₈-carbonilo, halo-alquilo C₁₋₈-carbonilo hidroxi-alquilo C₁₋₈-carbonilo o alcoxilo C₁₋₈-alquilo C₁₋₈-carbonilo; en donde heterociclilo se selecciona a partir de oxiranilo, aziridinilo, oxetanilo, tietanilo, azetidinilo, pirrolidinilo, tetrahidro-furanilo, tetrahidro-tiofenilo, 2,3-dihidro-furanilo, 2,5-dihidro-furanilo, 2,3-dihidro-tiofenilo, 1-pirrolinilo, 2-pirrolinilo, 3-pirrolinilo, tetrahidro-piranilo, piperidinilo, tetrahidro-tiopiranilo, morfolinilo, tiomorfolinilo, piperazinilo, azepanilo, tiepanilo u oxepanilo; cada uno de los cuales está insustituido o sustituido por 1 a 5 sustituyentes seleccionados independientemente a partir de oxo, halógeno, alquilo C₁₋₈, halo-alquilo C₁₋₈, hidroxi-alquilo C₁₋₈, hidroxilo, alcoxilo C₁₋₈, alcoxilo C₁₋₈-alquilo C₁₋₈, amino, N-alquilo C₁₋₈-amino, N,N-di-alquilo C₁₋₈-amino, alquilo C₁₋₈-carbonilo, halo-alquilo C₁₋₈-carbonilo hidroxi-alquilo C₁₋₈-carbonilo o alcoxilo C₁₋₈-alquilo C₁₋₈-carbonilo; en donde heterociclilo se puede unir en un heteroátomo o en un átomo de carbono, y en donde los heteroátomos de N y/o S también se pueden oxidar opcionalmente hasta diferentes estados de oxidación; en donde heteroarilo se selecciona a partir de: furanilo, tiofenilo, pirrolilo, imidazolilo, pirazolilo, tiazolilo, isotiazolilo, oxazolilo, isoxazolilo, 1,2,5-oxadiazolilo, 1,2,4-oxadiazolilo, 1,2,3-oxadiazolilo, 1,3,4-oxadiazolilo, 1,2,5-tiadiazolilo, 1,2,4-tiadiazolilo, 1,2,3-tiadiazolilo, 1,3,4-tiadiazolilo, 1,2,3-triazolilo, 1,2,4-triazolilo, 1,2,5-triazolilo, piridilo, pirimidinilo, pirazinilo, piridazinilo, 1,2,3-triazinilo, 1,2,4-triazinilo o 1,3,5-triazinilo; cada uno de los cuales está insustituido o sustituido por 1 a 5 sustituyentes seleccionados independientemente a partir de halógeno, alquilo C₁₋₈, halo-alquilo C₁₋₈, hidroxi-alquilo C₁₋₈, hidroxilo, alcoxilo C₁₋₈, alcoxilo C₁₋₈-alquilo C₁₋₈, amino, N-alquilo C₁₋₈-amino, N,N-di-alquilo C₁₋₈-amino, alquilo C₁₋₈-carbonilo, halo-alquilo C₁₋₈-carbonilo, hidroxi-alquilo C₁₋₈-carbonilo o alcoxilo C₁₋₈-alquilo C₁₋₈-carbonilo; en donde heteroarilo se puede unir en un heteroátomo o en un átomo de carbono, y en donde los heteroátomos de N y/o S también se pueden oxidar opcionalmente hasta diferentes estados de oxidación; R² se selecciona a partir de fenilo, naftilo, piridilo, pirimidinilo, pirazinilo, piridazinilo, quinolinilo o isoquinolinilo, cada uno de los cuales está insustituido o sustituido por 1 a 5 sustituyentes seleccionados independientemente a partir de halógeno, ciano, nitro, alquilo C₁₋₈, halo-alquilo C₁₋₈, hidroxi-alquilo C₁₋₈ hidroxilo, alcoxilo C₁₋₈, alcoxilo C₁₋₈-alquilo C₁₋₈, amino, N-alquilo C₁₋₈-amino, N,N-di-alquilo C₁₋₈-amino, alquilo C₁₋₈-carbonilo, halo-alquilo C₁₋₈-carbonilo, hidroxi-alquilo C₁₋₈-carbonilo o alcoxilo C₁₋₈-alquilo C₁₋₈-carbonilo; R³ se selecciona a partir de H o alquilo C₁₋₄; y m se selecciona a partir de 0 ó 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36158910P | 2010-07-06 | 2010-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115927A2 true AR115927A2 (es) | 2021-03-10 |
Family
ID=44532774
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102390A AR084970A1 (es) | 2010-07-06 | 2011-07-04 | Derivados de tetrahidro-pirido-pirimidina, una composicion farmaceutica en base al compuesto y un proceso para su preparacion |
| ARP190102244A AR115927A2 (es) | 2010-07-06 | 2019-08-07 | Derivados de tetrahidro-pirido-pirimidina |
| ARP200101358A AR118919A2 (es) | 2010-07-06 | 2020-05-12 | Derivados de tetrahidro-pirido-pirimidina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102390A AR084970A1 (es) | 2010-07-06 | 2011-07-04 | Derivados de tetrahidro-pirido-pirimidina, una composicion farmaceutica en base al compuesto y un proceso para su preparacion |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101358A AR118919A2 (es) | 2010-07-06 | 2020-05-12 | Derivados de tetrahidro-pirido-pirimidina |
Country Status (39)
| Country | Link |
|---|---|
| US (10) | US8653092B2 (es) |
| EP (1) | EP2590974B1 (es) |
| JP (1) | JP5770842B2 (es) |
| KR (1) | KR101560066B1 (es) |
| CN (1) | CN102971317B (es) |
| AR (3) | AR084970A1 (es) |
| AU (1) | AU2011275777C1 (es) |
| BR (1) | BR112013000275B1 (es) |
| CA (1) | CA2802132C (es) |
| CL (1) | CL2013000033A1 (es) |
| CO (1) | CO6670566A2 (es) |
| CR (1) | CR20130004A (es) |
| DK (1) | DK2590974T3 (es) |
| DO (1) | DOP2013000027A (es) |
| EA (1) | EA024123B1 (es) |
| EC (1) | ECSP13012420A (es) |
| ES (1) | ES2494718T3 (es) |
| GT (1) | GT201300009A (es) |
| HR (1) | HRP20140778T1 (es) |
| IL (1) | IL223795A (es) |
| JO (1) | JO2939B1 (es) |
| MA (1) | MA34361B1 (es) |
| MX (1) | MX2012015088A (es) |
| MY (1) | MY166026A (es) |
| NI (1) | NI201300002A (es) |
| NZ (1) | NZ604302A (es) |
| PE (1) | PE20130650A1 (es) |
| PH (1) | PH12013500031A1 (es) |
| PL (1) | PL2590974T3 (es) |
| PT (1) | PT2590974E (es) |
| RS (1) | RS53490B1 (es) |
| SG (1) | SG186187A1 (es) |
| SI (1) | SI2590974T1 (es) |
| TN (1) | TN2012000578A1 (es) |
| TW (1) | TWI534145B (es) |
| UA (1) | UA112517C2 (es) |
| UY (1) | UY33486A (es) |
| WO (1) | WO2012004299A1 (es) |
| ZA (1) | ZA201209117B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| CA2840315A1 (en) | 2011-06-27 | 2013-01-03 | Novartis Ag | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
| DK2790705T3 (en) * | 2011-12-15 | 2018-03-12 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| JO3398B1 (ar) | 2011-12-22 | 2019-10-20 | Novartis Ag | مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي |
| JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
| AU2013347538B2 (en) | 2012-11-16 | 2017-04-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| RU2661896C2 (ru) * | 2012-11-16 | 2018-07-23 | Мерк Шарп И Доум Корп. | Пуриновые ингибиторы фосфатидилинозитол-3-киназы дельта человека |
| EP2742940B1 (en) | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| WO2015162584A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide |
| GB201506786D0 (en) * | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
| EP3292120B1 (en) * | 2015-05-04 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections |
| AU2016362129A1 (en) | 2015-12-04 | 2018-06-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| ES2797091T3 (es) * | 2016-02-10 | 2020-12-01 | Novartis Ag | Uso de inhibidores de la actividad o de la función de la PI3K para el tratamiento del síndrome de Sjögren primario |
| SG11201907434RA (en) | 2017-03-22 | 2019-10-30 | Novartis Ag | Compositions and methods for immunooncology |
| EP3630116B1 (en) | 2017-05-26 | 2024-05-01 | The Board Of Regents Of The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| IL271930B (en) | 2017-07-13 | 2022-07-01 | Univ Texas | Heterocyclic inhibitors of atr kinase |
| US10800774B2 (en) | 2017-08-17 | 2020-10-13 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
| CN112218631B (zh) | 2018-03-16 | 2023-12-22 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
| CN114315826B (zh) * | 2021-11-30 | 2023-05-16 | 西安交通大学 | 一种吡啶并嘧啶类化合物及其应用 |
| KR20230160977A (ko) | 2022-05-17 | 2023-11-27 | 에이치앤오바이오시스(주) | 항암 치료에 사용되는 5종 이상의 생약 추출물 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1197466B (de) | 1962-03-22 | 1965-07-29 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5300645A (en) | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| CZ1598A3 (cs) | 1995-07-06 | 1998-04-15 | Novartis Ag | Pyrrolopyrimidiny a způsoby jejich přípravy |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GEP20012442B (en) | 1996-04-12 | 2001-05-25 | Warner Lambert Co | Irreversible Inhibitors of Tyrosine Kinases |
| CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| AU716610B2 (en) | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
| DE69724269T2 (de) | 1996-09-06 | 2004-06-09 | Obducat Ab | Verfahren für das anisotrope ätzen von strukturen in leitende materialien |
| CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CN1196698C (zh) | 1996-11-18 | 2005-04-13 | 生物技术研究有限公司(Gbf) | Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用 |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US5939421A (en) * | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| EP1058679B1 (en) | 1998-02-25 | 2005-10-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
| WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| BRPI0115193B1 (pt) | 2000-11-07 | 2016-08-09 | Novartis Ag | derivados de indolilmaleimida, processo para preparação dos mesmos, bem como composição farmacêutica que os compreende |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
| EP1578411A4 (en) | 2002-12-09 | 2007-05-02 | Univ Texas | PROCESS FOR THE SELECTIVE INHIBITION OF JANUS TYROSINE KINASE3 (JAK3) |
| HRP20050593A2 (en) | 2002-12-27 | 2006-03-31 | Instituto di Ricerche di Biologia Molecolare P. An | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
| US20080207613A1 (en) | 2004-01-12 | 2008-08-28 | Cytopia Research Pty Ltd | Selective Kinase Inhibitors |
| CA2553969A1 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| PL2298768T3 (pl) | 2004-06-11 | 2013-03-29 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu |
| US20060128710A1 (en) | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| ES2552804T3 (es) * | 2005-05-04 | 2015-12-02 | Evotec Ag | Compuestos heterocíclicos condensados, y sus composiciones y usos |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ES2566387T3 (es) * | 2007-04-02 | 2016-04-12 | Evotec Ag | Compuestos heterocíclicos condensados de pirid-2-ilo, y composiciones y usos de los mismos |
| DK2139334T3 (da) * | 2007-04-17 | 2013-09-23 | Evotec Ag | Kondenserede heterocykliske 2-cyanophenylforbindelser og sammensætninger og anvendelser deraf |
| WO2009047255A1 (en) | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| WO2009076631A1 (en) | 2007-12-12 | 2009-06-18 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| US8436005B2 (en) | 2008-04-03 | 2013-05-07 | Abbott Laboratories | Macrocyclic pyrimidine derivatives |
| US20120028940A1 (en) | 2008-09-16 | 2012-02-02 | Merck Sharp & Dohme Corp. | Functionally selective azanitrile alpha-2c adrenoreceptor agonists |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US8759362B2 (en) | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
| US8546388B2 (en) | 2008-10-24 | 2013-10-01 | Purdue Pharma L.P. | Heterocyclic TRPV1 receptor ligands |
| JP2010105951A (ja) | 2008-10-29 | 2010-05-13 | Dainippon Sumitomo Pharma Co Ltd | ６−アルキル置換テトラヒドロピリド［４，３−ｄ］ピリミジン誘導体 |
| WO2010117425A1 (en) | 2009-03-31 | 2010-10-14 | Biogen Idec Ma Inc. | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| WO2010120991A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses |
| WO2010127212A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| WO2010138430A1 (en) | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| SG182343A1 (en) | 2010-01-06 | 2012-08-30 | Joseph P Errico | Methods and compositions of targeted drug development |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| WO2011143495A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
| EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| DK2790705T3 (en) | 2011-12-15 | 2018-03-12 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
-
2011
- 2011-06-07 UA UAA201213598A patent/UA112517C2/uk unknown
- 2011-07-01 US US13/175,050 patent/US8653092B2/en active Active
- 2011-07-04 AR ARP110102390A patent/AR084970A1/es not_active Application Discontinuation
- 2011-07-05 TW TW100123736A patent/TWI534145B/zh active
- 2011-07-05 JO JO2011215A patent/JO2939B1/en active
- 2011-07-06 MY MYPI2012005385A patent/MY166026A/en unknown
- 2011-07-06 EA EA201291317A patent/EA024123B1/ru not_active IP Right Cessation
- 2011-07-06 UY UY0001033486A patent/UY33486A/es active IP Right Grant
- 2011-07-06 HR HRP20140778AT patent/HRP20140778T1/hr unknown
- 2011-07-06 SG SG2012089496A patent/SG186187A1/en unknown
- 2011-07-06 DK DK11730637.3T patent/DK2590974T3/da active
- 2011-07-06 MA MA35527A patent/MA34361B1/fr unknown
- 2011-07-06 PT PT117306373T patent/PT2590974E/pt unknown
- 2011-07-06 CA CA2802132A patent/CA2802132C/en active Active
- 2011-07-06 PL PL11730637T patent/PL2590974T3/pl unknown
- 2011-07-06 SI SI201130220T patent/SI2590974T1/sl unknown
- 2011-07-06 EP EP11730637.3A patent/EP2590974B1/en active Active
- 2011-07-06 ES ES11730637.3T patent/ES2494718T3/es active Active
- 2011-07-06 WO PCT/EP2011/061393 patent/WO2012004299A1/en not_active Ceased
- 2011-07-06 NZ NZ604302A patent/NZ604302A/en unknown
- 2011-07-06 CN CN201180033521.1A patent/CN102971317B/zh active Active
- 2011-07-06 PH PH1/2013/500031A patent/PH12013500031A1/en unknown
- 2011-07-06 AU AU2011275777A patent/AU2011275777C1/en active Active
- 2011-07-06 JP JP2013517375A patent/JP5770842B2/ja active Active
- 2011-07-06 RS RS20140427A patent/RS53490B1/sr unknown
- 2011-07-06 KR KR1020137000230A patent/KR101560066B1/ko active Active
- 2011-07-06 BR BR112013000275-1A patent/BR112013000275B1/pt active IP Right Grant
- 2011-07-06 MX MX2012015088A patent/MX2012015088A/es active IP Right Grant
- 2011-07-06 PE PE2013000017A patent/PE20130650A1/es active IP Right Grant
-
2012
- 2012-12-03 ZA ZA2012/09117A patent/ZA201209117B/en unknown
- 2012-12-06 TN TNP2012000578A patent/TN2012000578A1/en unknown
- 2012-12-20 IL IL223795A patent/IL223795A/en active IP Right Grant
-
2013
- 2013-01-03 CO CO13001273A patent/CO6670566A2/es active IP Right Grant
- 2013-01-04 GT GT201300009A patent/GT201300009A/es unknown
- 2013-01-04 CL CL2013000033A patent/CL2013000033A1/es unknown
- 2013-01-07 NI NI201300002A patent/NI201300002A/es unknown
- 2013-01-07 CR CR20130004A patent/CR20130004A/es unknown
- 2013-02-01 DO DO2013000027A patent/DOP2013000027A/es unknown
- 2013-02-04 EC ECSP13012420 patent/ECSP13012420A/es unknown
-
2014
- 2014-01-09 US US14/151,796 patent/US9499536B2/en active Active
-
2016
- 2016-10-05 US US15/285,614 patent/US20170022199A1/en not_active Abandoned
-
2017
- 2017-06-05 US US15/613,560 patent/US20170267678A1/en not_active Abandoned
-
2018
- 2018-05-30 US US15/993,051 patent/US20180265509A1/en not_active Abandoned
- 2018-10-17 US US16/163,106 patent/US20190040061A1/en not_active Abandoned
-
2019
- 2019-03-28 US US16/367,525 patent/US20190218217A1/en not_active Abandoned
- 2019-08-07 AR ARP190102244A patent/AR115927A2/es unknown
-
2020
- 2020-05-12 AR ARP200101358A patent/AR118919A2/es unknown
- 2020-06-30 US US16/916,168 patent/US20200392132A1/en not_active Abandoned
-
2021
- 2021-08-11 US US17/399,090 patent/US20220267318A1/en not_active Abandoned
-
2023
- 2023-11-08 US US18/504,244 patent/US20250059181A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115927A2 (es) | Derivados de tetrahidro-pirido-pirimidina | |
| BR112013010552A2 (pt) | derivado de piridina e agente medicinal | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| ES2640049T3 (es) | Derivados de 3,6-dihidropirimidina 2,4,5,6-sustituidos como inhibidores de la polimerasa del virus de la hepatitis B (VHB) para el tratamiento de, por ejemplo, la hepatitis crónica | |
| CO6241124A2 (es) | Moduladores de gamma secretasa | |
| AR108745A1 (es) | Derivados de oxadiazol microbiocidas | |
| AR088692A1 (es) | Derivados de 2-(1,2,3-triazol-2-il)benzamina y 3-(1,2,3-triazol-2-il)picolinamida | |
| AR086198A1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen | |
| BRPI0821653B8 (pt) | composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR096757A1 (es) | Inhibidores de bromodominios | |
| AR092684A1 (es) | Compuestos de sulfonamida sustituidos | |
| AR083872A1 (es) | Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep | |
| ME02729B (me) | Indolski i indazolski spojevi koji aktiviraju ampk | |
| AR095601A1 (es) | Diazilhidrazinas que contienen boro | |
| HRP20201171T1 (hr) | Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti | |
| BRPI1007456A2 (pt) | derivados de azaespiranil-alquilcarbamatos de compostos heterocíclicos com 5 membros, o respectivo preparo e a respectiva aplicação em terapêutica | |
| EA201401083A1 (ru) | Применение ингибиторов ccr3 | |
| AR086590A1 (es) | Compuestos de ciclohexanona y herbicidas que los comprenden | |
| AR104533A1 (es) | Derivados de ácido ciclopropano carboxílico y sus usos como inhibidores de leucotrieno c₄ sintasa | |
| AR114237A1 (es) | Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico | |
| RU2018143994A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2014526533A5 (es) | ||
| AR113839A1 (es) | Antagonistas del receptor b2 de bradiquinina | |
| JP2013542267A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |